Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Intermittent dosing of dasatinib with a once daily regimen has been shown to reduce side effects while preserving clinical efficacy in early and advanced phase chronic myeloid leukemia (CML). Yet, hematologic toxicity and fluid retention demand a dose modification or treatment discontinuation in selected patients. Patients resistant or intolerant to imatinib were retrospectively evaluated based on the toxicity-guided administration of a dose-reduced dasatinib regimen. Patients were treated with an on/off regimen (3 to 5 days on, 2 to 4 days off) to allow regression of dasatinib-dependent off-target toxicity. Patients were followed up by routine hematologic and cytogenetic assessment and molecular monitoring to safeguard clinical response to the altered drug schedule. Thirty-three CML patients primarily in chronic phase with imatinib intolerance (n = 11) or resistance (n = 22) were investigated. Nonexclusive reasons for dose reduction were hematologic toxicity (17/33, 51%) and pleural effusions (18/33, 55%). On/off treatment with a weekend drug holiday significantly reduced pleural effusions and hematologic toxicity. Eighteen of 31 (58%) patients showed effective disease control despite reduced total weekly dasatinib doses, either demonstrated by achieving an improved response level (12/31) or keeping the response level achieved by conventional continuous dosing (6/31). Of note, 10/12 patients with subsequently improved response have been treated for a minimum of 6 months with…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Most potential side-effects of D can be avoided though intermittent administration and, generally, serious side effects of D reverse upon temporary discontinuation [62,63], increasing the value of the opportunity to administer D intermittently, yet still benefit from its senolytic effects.”
Citations
Cites
A small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892 · cited 1×
“imatinib or the imatinib-derivative nilotinib [4, 5].”
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796 · cited 1×
“Thus, the dogma fueled by murine models of CML that continuous target inhibition is a prerequisite for effective leukemic cell kill can no longer be upheld for dasatinib, which represents a different class of ABLtargeting inhibitors with reduced selectivity and enhanced potency [5, 22, 23].”
BackgroundDasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760 · cited 3×
“However, clinical results demonstrated equal disease control with reduced toxicity in patients treated with a once daily (QD) regimen (1×100 mg) [3].”
BackgroundDasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Kantarjian, H., Shah, N. P., Hochhaus, A., Cortes, J., Shah, S., Ayala, M., Moiraghi, B., Shen, Z., Mayer, J., Pasquini, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002315 · Cited by 1,589 · cited 1×
“Toxicity rates are higher in patients treated with second-line compared to first-line patients with the marked difference that patients in the secondline study had a median age of 59 vs 47 years in the first-line DASISION study [11, 12].”
ResultSelf-citationBaccarani, M., Cortes, J., Pane, F., Niederwieser, D., Saglio, G., Apperley, J., Cervantes, F., Deininger, M., Gratwohl, A., Guilhot, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0779 · Cited by 1,291 · cited 2×
“Clinical response was assessed using the European LeukemiaNet criteria [14].”
BackgroundMethodSelf-citationO'Hare, T., Walters, D. K., Stoffregen, E. P., Jia, T., Manley, P. W., Mestan, J., Cowan-Jacob, S. W., Lee, F. Y., Heinrich, M. C., Deininger, M. W. N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0259 · Cited by 1,036 · cited 2×
“imatinib or the imatinib-derivative nilotinib [4, 5].”
BackgroundDruker, B. J., & Lydon, N. B. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9083 · Cited by 707 · cited 1×
“This suggested that a twice daily dosing (BID) regimen (2× 50 mg) would be necessary for continuous kinase inhibition, which was believed to be a dominant response-determining variable [7].”
BackgroundClinical Pharmacokinetics of Imatinib
Peng, B., Lloyd, P., & Schran, H. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544090-00001 · Cited by 665 · cited 1×
“Furthermore, dasatinib in comparison to imatinib, which has a plasma half-life of 19 h, has a significantly shortened plasma half-life of 3 to 5 h preventing patients from repetitive subtherapeutic drug levels that might promote the development of resistance [24, 25].”
BackgroundKantarjian, H. M., Shah, N. P., Cortes, J. E., Baccarani, M., Agarwal, M. B., Undurraga, M. S., Wang, J., Kassack Ipiña, J. J., Kim, D.-W., Ogura, M., et al. (2012) · Blood · doi:10.1182/blood-2011-08-376087 · Cited by 610 · cited 2×
“The DASISION study group reported on the randomized first-line treatment of CML patients with dasatinib or imatinib [2].”
BackgroundSelf-citationHochhaus, A., Kantarjian, H. M., Baccarani, M., Lipton, J. H., Apperley, J. F., Druker, B. J., Facon, T., Goldberg, S. L., Cervantes, F., Niederwieser, D., et al. (2007) · Blood · doi:10.1182/blood-2006-09-047266 · Cited by 609
Self-citation
Cited by
Hickson, L. J., Langhi Prata, L. G. P., Bobart, S. A., Evans, T. K., Giorgadze, N., Hashmi, S. K., Herrmann, S. M., Jensen, M. D., Jia, Q., Jordan, K. L., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.08.069 · Cited by 1,383
“Most potential side-effects of D can be avoided though intermittent administration and, generally, serious side effects of D reverse upon temporary discontinuation [62,63], increasing the value of the opportunity to administer D intermittently, yet still benefit from its senolytic effects.”
BackgroundSteegmann, J. L., Baccarani, M., Breccia, M., Casado, L. F., García-Gutiérrez, V, Hochhaus, A., Kim, D.-W., Kim, T. D., Khoury, H. J., Le Coutre, P., et al. (2016) · Leukemia · doi:10.1038/leu.2016.104 · Cited by 482
Self-citationPediatric chronic myeloid leukemia is a unique disease that requires a different approach
Hijiya, N., Schultz, K. R., Metzler, M., Millot, F., & Suttorp, M. (2016) · Blood · doi:10.1182/blood-2015-06-648667 · Cited by 214
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Shah, N. P., Bhatia, R., Altman, J. K., Amaya, M. L., Begna, K. H., Berman, E., Chan, O., Clements, J., Collins, R. H., Curtin, P. T., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0007 · Cited by 194
Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety
García‐Gutiérrez, V., & Hernández‐Boluda, J. C. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00603 · Cited by 154
Metadata
- Authors
- La Rosée, P., Martiat, P., Leitner, A., Klag, T., Müller, M. C., Erben, P., Schenk, T., Saussele, S., & Hochhaus, A.
- Affiliations
- Institut Jules Bordet (BE)
- Heidelberg University (DE)
- Jena University Hospital (DE)
- Venue
- Annals of Hematology
- Published
- 2013-04-28
- Volume
- 92
- Issue
- 10
- Pages
- 1345-1350
- ISSN
- 0939-5555 (ISSN-L)
- 1432-0584
- OpenAlex
- W2003589239
- Cited by
- 50
- References
- 27
- Citations by year
- 2025: 3 · 2024: 4 · 2023: 3 · 2022: 1 · 2021: 7 · 2020: 5 · 2019: 4 · 2018: 6 · 2017: 1 · 2016: 6 · 2015: 5 · 2014: 3 · 2013: 2
- FWCI
- 3.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Annals of Hematology (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- dasatinib, chronic myeloid leukemia, intermittent dosing, imatinib resistance, imatinib intolerance, dose reduction, pleural effusion, hematologic toxicity, fluid retention, off-target toxicity, treatment tolerability
- MeSH terms
- Imatinib Mesylate, Dasatinib, Adult, Aged, Aged, 80 and over, Benzamides, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Piperazines, Pyrimidines, Retrospective Studies, Thiazoles, Leukemia, Myeloid, Chronic-Phase, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib. https://app.cochat.ai/papers/10.1007/s00277-013-1769-2
- The paper
- La Rosée, P., Martiat, P., Leitner, A., Klag, T., Müller, M. C., Erben, P., Schenk, T., Saussele, S., & Hochhaus, A. (2013). Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib. Annals of Hematology. https://doi.org/10.1007/s00277-013-1769-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.